A Study of Sigvotatug Vedotin in Advanced Solid Tumors

2023-508469-34-00 Protocol C5751001 /SGNB6A-001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 14 Oct 2020 · Status Ongoing, recruiting · 2 EU/EEA countries · 15 sites · Protocol C5751001 /SGNB6A-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 1,006
Countries 2
Sites 15

Esophageal cancer

Key facts

Sponsor
Seagen Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
14 Oct 2020 → ongoing
Decision date (initial)
2024-05-27
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-508469-34-00
EudraCT number
2020-001035-27
ClinicalTrials.gov
NCT04389632

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Esophageal cancer

VersionLevelCodeTermSystem organ class
20.0 PT 10006187 Breast cancer 100000004864
20.0 PT 10033128 Ovarian cancer 100000004864
21.1 PT 10067821 Head and neck cancer 100000004864
21.1 PT 10017758 Gastric cancer 100000004864
21.0 LLT 10033604 Pancreatic cancer 10029104
20.0 PT 10040808 Skin cancer 100000004864
21.1 LLT 10008229 Cervical cancer 10029104
21.0 LLT 10015362 Esophageal cancer 10029104
21.1 PT 10061873 Non-small cell lung cancer 100000004864
20.0 PT 10005003 Bladder cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Seagen Inc.

Sponsor organisation
Seagen Inc.
Address
21823 30th Drive Southeast
City
Bothell
Postcode
98021-3907
Country
United States

Scientific contact point

Organisation
Seagen Inc.
Contact name
Clinical Medical Lead

Public contact point

Organisation
Seagen Inc.
Contact name
Clinical Medical Lead

Locations

2 EU/EEA countries · 15 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 150 5
Spain Ongoing, recruiting 88 10
Rest of world
United States, Switzerland, Korea, Republic of, Canada, Taiwan, United Kingdom
768

Investigational sites

France

5 sites · Ongoing, recruiting
Centre Hospitalier Universitaire De Poitiers
Service d'Oncologie Méicale, 2 Rue De La Miletrie, 86000, Poitiers
Centre Hospitalier Universitaire D'Angers
Service de Pneumologie, 4 Rue Larrey, 49100, Angers
Institut Gustave Roussy
Département d’Innovation Thérapeutique et d’Essais, Précoces (DITEP), 114 Rue Edouard Vaillant, 94800, Villejuif
Institut De Cancerologie De Lorraine
Département d'Oncologie Médicale, 6 Avenue De Bourgogne, 54500, Vandouvre Les Nancy
Centre Antoine Lacassagne
Département d'Oncologie Médicale, 33 Avenue De Valombrose, 06189, Nice Cedex 2

Spain

10 sites · Ongoing, recruiting
Hospital Quironsalud Malaga
Oncología Médica, Avenida Imperio Argentina 1, 29004, Malaga
Hospital Universitario Marques De Valdecilla
Servicio de Oncologia, Avenida Valdecilla Sn, 39008, Santander
Hospital Universitario Ramon Y Cajal
Servicio de Oncología Médica, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Hospital De Jerez De La Frontera
UGC Oncologia Medica, Carretera De La Ronda Circunvalacion S/n, 11407, Jerez De La Frontera
Vall D Hebron Institute Of Oncology
Unidad Investigacion Terapia Molecular - VHIO, Calle Natzaret 115, 08035, Barcelona
Hospital Universitario 12 De Octubre
Oncologia, Bloque D, Avenida De Cordoba Sn, Madrid
Hospital Quironsalud Barcelona
Oncología Médica. Unidad NEXT Oncology, Placa D'alfonso Comin 5-7, 08023, Barcelona
Hospital General Universitario De Elche
Servicio de Oncología Médica, Edificio 2, Camino De La Almazara 11, Elche
Hospital Universitario Hm Sanchinarro
Unidad de Ensayos Clínicos START Madrid # CIOCC, Calle Ona 10, 28050, Madrid
Hospital Hm Nou Delfos
Unidad de Ensayos Clínicos START Barcelona, Avinguda De Vallcarca 151, 08023, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2020-12-22 2021-01-05
Spain 2020-10-14 2020-11-16

Application history

8 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-30 Spain Acceptable
2024-05-20
2024-05-20
2 SUBSTANTIAL MODIFICATION SM-1 2024-08-01 Spain Acceptable
2024-10-24
2024-10-24
3 SUBSTANTIAL MODIFICATION SM-2 2024-12-09 Spain Acceptable
2025-04-04
2025-04-04
4 NON SUBSTANTIAL MODIFICATION NSM-1 2025-04-08 Spain 2025-04-08
5 SUBSTANTIAL MODIFICATION SM-3 2025-05-12 Spain Acceptable
2025-06-24
2025-06-25
6 SUBSTANTIAL MODIFICATION SM-4 2025-07-11 Spain Acceptable
2025-08-19
2025-08-19
7 SUBSTANTIAL MODIFICATION SM-5 2025-10-06 Spain Acceptable
2026-01-14
2026-01-14
8 SUBSTANTIAL MODIFICATION SM-6 2026-01-26 Spain Acceptable
2026-03-16
2026-03-23